Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 321.66M P/E - EPS this Y -3.60% Ern Qtrly Grth -
Income -51.92M Forward P/E -10.81 EPS next Y - 50D Avg Chg 45.00%
Sales 194.62M PEG - EPS past 5Y - 200D Avg Chg 127.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -6.00%
Recommedations 1.70 Quick Ratio 0.82 Shares Outstanding 209.37M 52W Low Chg 618.00%
Insider Own 2.47% ROA -9.31% Shares Float 188.22M Beta 0.84
Inst Own 26.27% ROE - Shares Shorted/Prior 13.40M/8.11M Price 1.73
Gross Margin 79.57% Profit Margin -26.68% Avg. Volume 2,142,154 Target Price 5.00
Oper. Margin 5.26% Earnings Date May 6 Volume 2,121,982 Change -5.98%
About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics, Inc. News
04/02/24 Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/28/24 FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
03/28/24 Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
03/27/24 Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
03/26/24 Akebia Awaits FDA Word On Second Crack At Vadadustat
08:25 AM Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
03/16/24 Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
03/14/24 Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
03/14/24 Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
03/14/24 Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
03/11/24 Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
01/30/24 Akebia Secures $55 Million Term Loan Financing
01/09/24 Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
12/20/23 Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/10/23 Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year
11/20/23 Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
11/09/23 Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript
11/08/23 Q3 2023 Akebia Therapeutics Inc Earnings Call
11/08/23 Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
11/02/23 Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
AKBA Chatroom

User Image Justinkorr Posted - 24 minutes ago

$AKBA Even though it is not a blockbuster drug, it is a company that has two new drugs. Nevertheless, it is surprising that the stock price is barely in a position to avoid delisting.

User Image stocktrader5252 Posted - 25 minutes ago

$AKBA Red PM. Red during the day. Red AH. Awesome 🙄

User Image Maiquyen003 Posted - 1 hour ago

$AKBA Let me show you how fake the current share price of AKBA is. On April 17, 2000, the share price was $7 and a cup of coffee at McDonald was $1. At that time, Vad was far from approval, and the company was losing money. Today, April 17, 2024, the share price is $1.40, and a cup of coffee at McDonald is $2.50. VAD is FDA approved and the company has net income for the first time in its history. In 2000, 1 share of AKBA bought you 7 cups of coffee, today it buys you less than 1 cup. Everything else, including medications for kidney patients, get adjusted upward due to inflation. Yet AKBA share price is being pushed downward by naked shorting for dark reasons. This is the game being played. They make you fearful by doing naked shorting to anchor the stock here. I know many retailers would eventually let go of their shares. But for me, I give them my middle finger. Or should I say it out loud: FY!

User Image Ianwalsh15 Posted - 1 hour ago

$AKBA pls don’t hire anyone 🤣

User Image Kickintheshorts Posted - 1 hour ago

$AKBA people seem to miss that JB announced in the CC of going after contracts. That said, he could announce any day of a contract/s. Would that not drive the SP higher? Of course it would. So, sit and watch no announcements and hope for a a lower buy in or get onboard as the PR’s release. Oh, and maybe a buyout….

User Image 45000sharesofakba Posted - 2 hours ago

$AKBA green tomorrow folks

User Image buythehornz127 Posted - 2 hours ago

$AKBA LAST BUYOUT POST - (1)Akebia’s expenses slashed 42%; (2)Bloomberg Terminal quote “Akebia & CSL’s Vadadustat” accurate; (3)CSL/Vifor - $85M+ reasons to b/o Akebia ($25M upfront, $20M equity purchase, $40M refundable capital investment). Agreement w/ Fresenius to distribute & sell drug; (4)CSL’s history of M&A - Vifor (2022), Vitaeri (2020), Novartis Influenza (2015), Aventis Behring (2004), Nabia Plasma (2001); (5)Hadas, CLO, Dahan, COO, Snow, CFO departing or have departed (June 14th, June 28th, March 22nd). No executive search committees; (6)BlackRock refinancing extends Akebia’s loan interest only period beyond catalysts; (7)Grund employed as CCO on irregular basis - “appointed” not “hired” by Akebia on Jan. 9th; (8)Butler assumed irregular role as Interim Principal Financial Officer along w/ President/CEO; (9)Medice/Akebia/Vifor delays. Vadadustat Europe launch 2023. USA launch 2024. Covid 19/ARDS trial 2023; (10)STA Pharma Hong Kong supply agreements renegotiated for M&A? GL

User Image Limey42 Posted - 2 hours ago


User Image Sovereign23 Posted - 3 hours ago

$AKBA Imagine this board when we have our next big rise… imagine we stay there and go even higher the next day… all the people you are theroizing with will be celebrating! I like this board and community a lot and we all look to be super bullish! We know what we own ! I don’t think I’m selling a share till 8.I know many will do the same…

User Image Kickintheshorts Posted - 3 hours ago

$AKBA if there was a gif of cows (with hair) enjoying 69 would have been a better post. Sadly, the new folks might not get it but let’s help bring them onboard. Bigger Boom!

User Image ClenchFists Posted - 3 hours ago

$AKBA Here we stay!! until our dream day arrives!!

User Image Kickintheshorts Posted - 3 hours ago

$AKBA I’m with Zank! Boom!

User Image SwingtradingSteve Posted - 3 hours ago

$AKBA if it drops more it's just free money 💰

User Image SwingtradingSteve Posted - 3 hours ago

$AKBA any price under 1.40 is fake manipulation and therefore it's a buy

User Image ZanklinFrappa Posted - 3 hours ago

$AKBA Can't lose on this one. Penetrating the US market next year, possibility of a buyout. I'm here, I'm holding, hope you are, too. Remaining

User Image Scorpio1313 Posted - 3 hours ago

$AKBA Billionaire Ray Dalio: “Trying to time the stock market is harder 'than competing in the Olympics” With that being said , hold onto your shares until something actually happens in the real time lol like a fucking buyout, new positive PR , or just old fashioned organic growth / net revenue. Patience with this particular stock is more bearable and tolerable than speculation lol ; I cannot believe I’m saying that ; I hate waiting lol!!! ; Listen no disrespect to those great minds who are analysing, gathering information, and constructing the buyout argument/theory. In my opinion, projections and speculations are meaningless and will drive you nuts and might lead to negative decision making ; we just learned our lesson few weeks ago from predicting all sorts of share prices upon FDA approval!!! All I’m saying ; It’ gonna happen regardless of your input because AKBA is circled by so many uncontrolled variables !!!!

User Image HyacinthCohen Posted - 4 hours ago

$AKBA anybody writing CCs? I want to, but I'm too chicken.

User Image Aamadeus Posted - 5 hours ago

$AKBA job drop it!

User Image Ianwalsh15 Posted - 5 hours ago

$AKBA day by day but I’ve got a feeling about may ☘️☘️

User Image roomza Posted - 5 hours ago

$AKBA DROP IT BUTLER! there is a very compelling argument for BO imho!!

User Image Bornjever Posted - 6 hours ago

$AKBA takes time to do something really good especially if the other folks are wanting to go down on the elevator and just a few of us end up having to walk up 50 floors now. I even had to bring a few of this life saving meals.

User Image Maiquyen003 Posted - 6 hours ago

$AKBA I’m smelling news soon!

User Image UTRrun Posted - 6 hours ago

$AKBA should get a 2 day bounce following XBI here into Friday. I would expect a close around 1.50 for options.

User Image Magic_Money Posted - 6 hours ago

$AKBA Shorts increase 33% in March and got nailed by approval, but because of the delay of launch until January of 2025 and no announcement of EU launch at the time, shorts got the opportunity to drive it back down and save their butts. This price action won’t last seeing EU launch is coming in May and TDAPA filling coming. Any other news on ARDS or NDD will just keep driving the SP up. EU sales should have spread to all the larger EU countries by 2025 US launch date and we will be in full gear come January 2025.

User Image Smolik Posted - 7 hours ago


User Image KarlDieGlatze Posted - 7 hours ago

$AKBA Further clarification for JB, because he is "a good steward." The time lag is our depreciating money in a highly inflationary environment where U.S. $ is under attack-unabated reduced purchasing power-in spite of the Fraudsters expecting or indicating "reversal" of "labor" and "other" inputs impossible to reverse unless "Depression."

User Image Maiquyen003 Posted - 7 hours ago

$AKBA same thing happened to vnda. They pushed it down to $3.7 and offered $7. The board rejected the offer!

User Image Maiquyen003 Posted - 7 hours ago

$AKBA It is being depressed so that a low offer can be made

User Image Maiquyen003 Posted - 8 hours ago

$AKBA added 18k shares

User Image Suman2627 Posted - 8 hours ago

$AKBA still holding strong even in red zone

Analyst Ratings
HC Wainwright & Co. Buy Mar 28, 24
HC Wainwright & Co. Buy Mar 15, 24
HC Wainwright & Co. Buy Nov 17, 23
HC Wainwright & Co. Buy Sep 27, 23
HC Wainwright & Co. Buy Aug 28, 23
HC Wainwright & Co. Neutral Aug 11, 23
HC Wainwright & Co. Neutral Jun 21, 23
HC Wainwright & Co. Neutral Jun 14, 23
HC Wainwright & Co. Neutral Jun 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hadas Nicole R. SVP, Chief Legal Off.. SVP, Chief Legal Officer May 24 Sell 1.22 63,186 77,087 524,344 05/25/23
Dahan Michel SVP, Chief Operating.. SVP, Chief Operating Officer May 24 Sell 1.22 95,478 116,483 574,037 05/25/23
Butler John P. CEO and President CEO and President Feb 28 Sell 2.17 79,026 171,486 1,403,247 03/02/22
Burke Steven Keith SVP, Chief Medical O.. SVP, Chief Medical Officer Feb 28 Sell 2.17 15,056 32,672 217,663 03/02/22
Cotreau Violetta SVP, Chief Accountin.. SVP, Chief Accounting Officer Feb 28 Sell 2.15 3,946 8,484 29,121 03/02/22
Dahan Michel SVP, Chief Operating.. SVP, Chief Operating Officer Feb 28 Sell 2.17 21,533 46,727 297,017 03/02/22
Faulkingham Dell SVP, CCO SVP, CCO Feb 28 Sell 2.17 13,184 28,609 173,841 03/02/22
Hadas Nicole R. SVP, Chief Legal Off.. SVP, Chief Legal Officer Feb 28 Sell 2.17 21,062 45,705 304,241 03/02/22
Spellman David A SVP, CFO and Treasur.. SVP, CFO and Treasurer Feb 28 Sell 2.16 8,203 17,718 128,599 03/02/22
Faulkingham Dell CCO CCO Mar 02 Sell 3.4 6,749 22,947 128,825 03/02/21
Hadas Nicole R. SVP, Chief Legal Off.. SVP, Chief Legal Officer Mar 02 Sell 3.4 14,285 48,569 263,171 03/02/21